SCN1A and migraine disorder: Such modeling provides a new tool for the exploration of peripheral mechanisms in trigeminal pain and suggests that molecules reducing, probably in a mutation-specific manner, the excessive activity of NaV1.1 channels could present a novel type of analgesic therapy for patients with migraine.